Early Access — free while we kick the tires
EdgarHawk

Klee Justin B.

Co-Chief Executive Officer

Director Officer
1 filing analyzed · 1 company · Latest 2026-01-20

Companies

Company Buys Sells Direction
Amylyx Pharmaceuticals, Inc. AMLX 0 4 Net selling

Activity

January 2026
high
Sell
138,188 shares
$1,877,570
Significance 6/10

Co-CEO Klee sells 138,188 shares in 2 transactions for $1.9M as AMLX stock surges 37.7% in 30 days

Klee Justin B., Co-Chief Executive Officer, executed 2 separate sales totaling 138,188 shares for $1,877,569.83 (blended average $13.59) on January 15-16, 2026. These sales represent a 3.9% reduction in his post-transaction holdings of 3,379,398 shares. The timing coincides with a sharp 37.7% rally over the preceding 30 days and placement near the 52-week high of $16.55, where the current price sits. The sales occurred while AMLX faces severe financial headwinds: the company reported zero revenue in the latest quarter, a negative net income of $-34,386,000, and annual revenue contraction of -77.1% year-over-year. A Co-CEO's substantial share disposition during a period of momentum, combined with the company's deteriorating operational metrics and cash burn, is material for investors evaluating management's commitment relative to public fundamentals.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access